NextCure reports Q3 EPS (51c), consensus (66c)

Reports Cash, cash equivalents, and marketable securities as of September 30, , were $118.2 M as compared to $159.9Mas of December 31, 2022. The decrease of $41.7M was primarily related to cash used to fund operations, and cash used to purchase fixed assets. Research and development expenses were $11M for the quarter ended September 30 as compared to $13.5M for the quarter ended September 30, 2022. The decrease of $2.5M was primarily related to lower costs related to our clinical programs.”We plan to provide updates on our clinical programs, including the Phase 1b trial of NC410 in combination with pembrolizumab in patients with solid tumors, the Phase 1b trial of NC762 targeting tumor types with high B7-H4 expression, and a Phase 1a operational update for NC525 treating patients with acute myeloid leukemia by the end of the year,” said Michael Richman, NextCure’s president and chief executive officer. “Our cash position and mid-2025 runway will support advancement of our most promising programs.”